LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the idiopathic pulmonary fibrosis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat idiopathic pulmonary fibrosis.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Idiopathic pulmonary fibrosis: Market overview
Idiopathic pulmonary fibrosis is a lung disorder that affects lung tissues, making them thick, stiff, and scarred. The scarring of these tissues gets worse over time, making it difficult for the person to breathe. With low levels of oxygen supply to the brain and other organs, tissues tend to lose their efficiency. IPF is usually found in middle-aged and older people. However, the severity of the disease may vary from person to person. IPF can be caused due to cigarette smoking, viral infections, and family history.
According to a senior analyst at Technavio for research on infectious and rare diseases, “IPF is one of the interstitial lung diseases. Presently, there is no cure for IPF. However, it can be treated with medication to ensure long-term survival. Researchers are finding new drugs and treatments for IPF, owing to technological advancements. The rate at which IPF progresses varies. It is stable for years in some patients and may rapidly worsen in some patients.”
Idiopathic pulmonary fibrosis: Segmentation analysis
This market research report segments the Idiopathic pulmonary fibrosis market based on therapies employed that includes (monotherapy, combination therapy, and unknown), RoA (oral, inhalation, intravenous, subcutaneous, and undisclosed), therapeutic modalities (small molecules, monoclonal antibodies, recombinant protein, stem cell, protein, antibody, and undisclosed), targets for drugs under development (integrin alphaV 6, GSNOR, CTGF, others, and undisclosed), drugs under development (discovery, pre-clinical, phase I, phase I/II, phase II, and phase III), MoA (GSNOR inhibitor, integrin alphaV 6 inhibitor, others, and undisclosed), and recruitment status (completed, recruiting, active not recruiting, not yet recruiting, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.